WHO WE ARE
As a family-held company, we are cognisant of how work shapes who we are and who we want to become. Our culture is enriched with a genuine ambition to make a mark, and together we strive to become individuals of remarkable value.
WHO WE ARE Aspiration & Values Leadership Our defining moments Sustainability Code of conduct Global presence
OUR FOCUS
We are a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia – a condition which more than 1 billion people live with, making it one of the largest global health challenges of our time.
OUR FOCUS Pharmaceuticals Carbohydrates Animal Health
PROGRAMMES
Discover our current research programme which highlight our commitment to groundbreaking studies and treatments, based on our expertise in iron metabolism.
PROGRAMMES Clinical Trials Petadeferitrin
CAREER
We are a fully integrated pharmaceutical company with many exciting opportunities ahead of us. Do you want to join us?
CAREER Job openings Life at Pharmacosmos
NEWS & MEDIA
We always strive to achieve new results and collaborations that can improve the quality of lives. Stay informed with our latest news and press releases.
NEWS & MEDIA News & Press Events Media
CONTACT US
We welcome all questions or inquiries. Get started by filling out a form or read about the way we are partnering.
CONTACT US Partnering with us Privacy policy

Home NEWS & MEDIA News & Press JACOB TOLSTRUP ELECTED NEW CHAIRMAN OF THE BOARD OF DIRECTORS OF PHARMACOSMOS

JACOB TOLSTRUP ELECTED NEW CHAIRMAN OF THE BOARD OF DIRECTORS OF PHARMACOSMOS

News and Press Releases

Date02.08.2024

At the extraordinary general meeting of Pharmacosmos A/S on 8 February 2019, Jacob Tolstrup was elected to the Board of Directors. At the same time, the Chairman of the Board of Directors Axel Kierkegaard stepped down from the Board of Directors. At the board meeting held immediately after the extraordinary general meeting, Jacob Tolstrup was elected Chairman of the Board.

Axel Kierkegaard was elected Chairman of the Board of Pharmacosmos in April 2002. During his tenure Pharmacosmos has seen incredible growth with sales increasing more than five-fold.

Lars Christensen, President & CEO commented: "Working together with Axel Kierkegaard and having him as an advisor has been a privilege for Pharmacosmos and for me personally. I would like to express my deepest gratitude for his effort and commitment over the years".

Jacob Tolstrup brings substantial pharmaceutical commercial expertise to Pharmacosmos with more than 20 years of experience in the pharmaceutical industry including approximately four years in the US. Jacob Tolstrup is Executive Vice President, Commercial Operations at H. Lundbeck A/S, and holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.

Tobias S. Christensen, Vice President, Corporate Development & Strategy said: "Jacob Tolstrup joining Pharmacosmos as our new Chairman of the Board is a big advantage for us as we continue our work to improve the treatment of iron deficiency We are looking forward to working with Jacob and will value his great experience as we continue to grow, not least as we work towards entering the US market with our human products"

Jacob Tolstrup, new Chairman of the Board commented: "Pharmacosmos is a very focused specialty pharma company with a strong potential for growth. I see the family-held ownership, the company culture and the inherent expertise as an excellent platform for future development of Pharmacosmos and I am looking forward to be a part of this".

FOR MORE INFORMATION

Tobias S. Christensen
Vice President, Corporate Development & Strategy
Tel: +45 5948 5959

Go to News & Press